Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia.

Yai Wen Choo Nurul-Ain Mohd-Tahir Mohd Shahrir Mohamed Said Shu Chuen Li Mohd Makmor Bakry

Published in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2022)

From the perspective of the Malaysian health care provider, denosumab appears to be a cost-effective treatment choice for postmenopausal osteoporotic women over 60 years of age.

Keyphrases

bone mineral density
postmenopausal women
healthcare
body composition
primary care
pregnant women
type diabetes
metabolic syndrome
breast cancer risk
skeletal muscle
health insurance
insulin resistance
pregnancy outcomes
health information
affordable care act